ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD) (“BioSphere”) today announced that a study published in the January 2008 issue of the Journal of Vascular and Interventional Radiology concluded that Uterine Artery (Fibroid) Embolization (UAE or UFE) performed using BioSphere’s Embosphere® Microspheres showed significantly better results in blocking the flow of blood from arteries that feed benign uterine fibroids compared to procedures performed using Boston Scientific’s Contour SE™ polyvinyl alcohol (PVA) embolic administered in accordance with Boston Scientific’s newly refined treatment protocol. Given their current understanding of the importance of blood vessel occlusion as an endpoint after UFE, the authors concluded that “…tris-acryl gelatin microspheres (Embosphere Microspheres) should be the preferred agent for UAE at this time.”
